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The synthesis and biological evaluation of novel 1-aryl-3-[2-, 3- or 4-(thieno[3,2-b]pyridin-7-ylthio)phe-
nyl]ureas 3, 4 and 5 as VEGFR-2 tyrosine kinase inhibitors, are reported. The 1-aryl-3-[3-(thieno[3,2-b]-
pyridin-7-ylthio)phenyl]ureas 4a–4h, with the arylurea in the meta position to the thioether, showed
the lowest IC50 values in enzymatic assays (10–206 nM), the most potent compounds 4d–4h (IC50 10–
28 nM) bearing hydrophobic groups (Me, F, CF3 and Cl) in the terminal phenyl ring. A convincing rational-
ization was achieved for the highest potent compounds 4 as type II VEGFR-2 inhibitors, based on the
simultaneous presence of: (1) the thioether linker and (2) the arylurea moiety in the meta position.
For compounds 4, significant inhibition of Human Umbilical Vein Endothelial Cells (HUVECs) prolifera-
tion (BrdU assay), migration (wound-healing assay) and tube formation were observed at low concentra-
tions. These compounds have also shown to increase apoptosis using the TUNEL assay. Immunostaining
for total and phosphorylated (active) VEGFR-2 was performed by Western blotting. The phosphorylation
of the receptor was significantly inhibited at 1.0 and 2.5 lM for the most promising compounds.
Altogether, these findings point to an antiangiogenic effect in HUVECs.
 2015 Elsevier Ltd. All rights reserved.1. Introduction
The Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2)
is a class V Receptor Tyrosine Kinase (RTK), expressed primarily
in endothelial cells, and is activated by the specific binding of
Vascular Endothelial Growth Factor (VEGF), secreted by endothe-
lial cells and various tumor cells, to the VEGFR-2 extracellular
regulatory domain. Once activated, VEGFR-2 undergoes autophos-
phorylation, triggering signalling pathways leading to endothelial
cell proliferation and subsequent tumor angiogenesis that pro-
motes tumor growth and metastasis.1 Several small-molecule
VEGFR-2 inhibitors have emerged as promising antiangiogenic
agents for treatment against a wide variety of cancers and act
by competing with adenosine triphosphate (ATP) for the ATP-
binding site of the VEGFR-2 intracellular kinase domain, therebypreventing the intracellular signalling. This leads to angiogenesis,2
the sprouting of new capillaries from pre-existing blood vessels,
which is a multistep process involving endothelial cell differenti-
ation, proliferation, migration, permeability and tube formation.
These assays are used to reproduce the angiogenesis process
in vitro.3
Most known kinase inhibitors are classified as type I kinase
inhibitors, which bind in and around the region occupied by the
adenine ring of ATP.4 Sunitinib is a classical example of a type I
inhibitor and has been approved for the treatment of renal cell car-
cinomas and gastrointestinal stromal tumors.5 On the other hand,
type II kinase inhibitors induce the inactive DFG-out conformation
of the activation loop, enabling them to occupy the adenine bind-
ing site and an adjacent hydrophobic pocket created by this rear-
rangement. As the residues forming the hydrophobic pocket are
less conserved than residues in the adenine pocket, type II inhibi-
tors usually provide a better kinase selectivity when compared to
type I inhibitors.4,6
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These inhibitors occupy the adenine pocket with a suitable ring
or ring system that is able to promote 1 to 3 H-bonds with the
kinase hinge region (Glu917-Cys919); while also occupying the
hydrophobic pocket that is available in the DFG-out conformation
(Asp1046-Phe1047-Gly1048 for VEGFR-2), with a suitable ring or
ring system. A pair of hydrogen bond donating and accepting
groups, (usually an urea or a corresponding bioisosteric core) is
also present to establish H-bonds with Asp1046 and Glu885. The
ring systems occupying both the adenine and the hydrophobic
pocket are usually linked via a central ring positioned in an inter-
mediate linker region (Figs. 1 and 2).
A number of type II VEGFR-2 inhibitors, relevant for the dis-
cussion of the results are presented in Figure 1. They present a
typical pharmacophore model for these inhibitors where a central
aryl ring, occupying the linker region, is bound to the ring occu-
pying the adenine pocket via an ether linker (O-linker), while the
ring in the hydrophobic pocket is bound to the central ring via an
urea group in para position to the O-linker. In the course of
molecular modelling studies performed in our group and follow-
ing a previous study presenting thieno[3,2-d]pyrimidines as
VEGFR-2 inhibitors, several observations suggested that alterna-
tives to the O-linker using different configuration patterns, could
be explored in an attempt to synthesize original VEGFR-2
inhibitors.10 Specifically the use of a thioether linker (S-linker)
instead of an ether linker (O-linker) could provide interesting
compounds with potent VEGFR-2 inhibition capability and with
an alternative profile to the existent type II VEGFR-2 inhibitor
scaffolds. Sorafenib was used for comparison with compounds
that present similar substituents in the terminal aryl ring located
in the hydrophobic pocket.
Herein, we describe an on-going effort to develop
novel small-molecule VEGFR-2 inhibitors, based on theS
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Figure 1. VEGFR-2 type II inhibitors presenting an O-linker in the para position relative
Tsukuba IC50 = 3.5 nM)8 and B (pyrrolo[3,2-d]pyrimidine derivative; IC50 = 6.2 nM).9thieno[3,2-b]pyridine-7-thioether-1,3-diarylurea scaffold. The
synthesis and the VEGFR-2 enzymatic inhibition activity assays
of a novel series of 1-aryl-3-[2-, 3- or 4-(thieno[3,2-b]pyridin-7-
ylthio)phenyl]ureas are presented. Docking simulations were
performed to analyze the binding mode of the more potent
synthetized compounds. The best compounds identified in
enzymatic assays were then tested in VEGF-stimulated Human
Umbilical Vein Endothelial Cells (HUVECs). Their proliferation,
apoptosis, migration and tube formation, VEGFR-2 expression
and activity were examined by BrdU, TUNEL, wound healing and
matrigel assays, and by Western blot, respectively.
2. Results and discussion
2.1. Synthesis
The 7-chlorothieno[3,2-b]pyridine 1,11a,b obtained from the
commercial 7-hydroxythieno[3,2-b]pyridine and POCl3, reacted
with 2-, 3- or 4-aminothiophenol in stoichiometric amounts in
DMF at 140 C for 2 h to give only the aminated di(hetero)
arylthioethers 2a–c by nucleophilic aromatic substitution, in very
good yields (Scheme 1). These were reacted with differently
substituted arylisocyanates in THF/CH2Cl2 at room temperature
for 12 h, to give the 1-aryl-3-[2-, 3- or 4-(thieno[3,2-b]pyridin-7-
ylthio)phenyl]ureas 3a–c, 4a–h and 5a–e in good yields
(Scheme 1). The synthesis of compounds 4d–h bearing
hydrophobic groups, was performed after the best results
obtained in enzymatic assays (Table 1) for the substitution
pattern of compounds 4a–4c. For compounds 5, based also in the
results of enzymatic assays (Table 1) that were not so good then
for series 4, only compounds with substituents that are present
in Sorafenib (Fig. 1) CF3 and/or Cl, were prepared in order to
evaluate their effects.orafenib
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Figure 2. Docking pose superimposition of: (A) compound 5a (green) and (B) compounds 4d and 4f (green), with the co-crystallized structure of compound B (cyan). A partial
surface representation of the VEGFR-2 kinase binding site is depicted with the relevant residues presented (white). H-bonds are represented in dashed red lines (distances
between 2.8 and 3.4 Å). Structures were prepared using PyMOL.18
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Scheme 1. Synthesis of the 2-, 3- or 4-(thieno[3,2-b]pyridin-7-ylthio)anilines 2a–c and of the 1-aryl-3-[2-, 3- or 4-(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas 3–5.
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Table 1
VEGFR-2 inhibition activity of compounds 3a–c, 4a–h and 5a–e
Compound VEGFR-2; IC50a (using 10 lM of ATP)
(nM)
3a >100,000
3b >100,000
3c >100,000
4a 94
4b 107
4c 206
4d 10
4e 28
4f 11
4g 15
4h 16
5a 1160
5b 1390
5c 8360
5d 988
5e 1947
Staurosporineb (enzymatic kit
control)
6
a Each IC50 determination is a result of at least four separate determinations.
b Staurosporine experimental VEGFR-2 IC50 = 7 nM.16
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Compounds 3a–c, 4a–c and 5a–c were first synthetized and
subsequently evaluated for their ability to interact with the
VEGFR-2 kinase domain (Table 1), using an enzymatic FRET-based
assay.12 The three series differ in the position of the arylurea scaf-
fold; with compounds 3, 4 and 5 bearing it in the ortho, meta and
para-position relative to the thioether linker, respectively. Com-
pounds 4a–c displayed the highest enzyme inhibition potency
with IC50 values of 94, 107 and 206 nM, respectively; whereas
compounds 5a, 5b displayed either moderate, 1160 and 1390 nM,
respectively, or 5c weak VEGFR-2 inhibition activity, 8360 nM;
compounds 3a–c were inactive. These findings are surprising as
compounds 5 present similarities with known VEGFR-2 inhibitors
with the arylurea moiety in the para position,8–10,13–15 including
the drug Sorafenib (Fig. 1).7 Instead, compounds 4a–4c with the
arylurea group in the meta position, were an order of magnitude
more potent. The arylurea in the meta position is usually not con-
sidered as a promising feature and the studies using different scaf-
folds as potential VEGFR-2 inhibitors always explore the arylurea
in the para position7–10,13–15 although presenting an O-linker
instead of a S-linker.
In fact, considering the number of scaffolds with VEGFR-2 inhi-
bitory activity already published, it is surprising that a S-linker in
meta position relative to the urea moiety was not explored before
by others. The explanation is probably inherent to the rational of
the drug design process where only one feature is explored at a
time. We have found at least two studies performed by Hasegawa
et al.8 and Oguro et al.9 where the importance of the O/S linker
atom and the meta/para position relative to the urea moiety was
analyzed in a series of benzimidazole and pyrrolo[3,2-d]pyrimidine
derivatives, respectively. These compounds explore the same
VEGFR-2 binding mode with the best clinical candidate provided
by each study presented as compound A (benzimidazole) and B
(pyrrolo[3,2-d]pyrimidine derivative) (Fig. 1). In both studies the
O/S-linker was investigated only in para position relative to the
urea moiety, with the S-linker always providing less potent com-
pounds and being discarded for further synthesis. In fact the pres-
ence of a S-linker, when compared to similar compounds with an
O-linker, lowered the VEGFR-2 inhibition potency by 3-fold and
20-fold for the benzimidazole and pyrrolo[3,2-d]pyrimidine
derivatives, respectively. Similarly, the meta/para position relative
to the urea was only investigated using an O-linker, with the metaposition always providing less potent compounds and thus also
being discarded for further synthesis. Also compounds with the
O-linker and urea in the meta position lowered the activity by 6-
fold and 55-fold for the benzimidazole and pyrrolo[3,2-d]pyrim-
idine derivatives, respectively, when compared to compounds with
the O-linker in the para position relative to the urea. As far as our
knowledge, this thieno[3,2-b]pyridine series is the first that pre-
sents compounds with a S-linker in the meta position relative to
the urea moiety with potent inhibition activity against VEGFR-2.
This study provides a new insight in the field as this substitution
pattern was not previously investigated and has been thought to
be of low potency.
Typically, for type II VEGFR-2 inhibitors, the terminal aryl ring
that occupies the hydrophobic pocket is functionalized with
hydrophobic substituent groups, the most frequent being methyl
groups or halogen atoms in meta or para position, although other
substitution pattern is observed (Fig. 1). Based on this information
compounds 4d–h were synthetized in an attempt to obtain more
potent VEGFR-2 inhibitors than compounds 4a–4c. Compounds
4d with a F atom in the para position or 4e with a F in the meta
position, 4f with a methyl group, 4g with a CF3 both in the meta
position and 4hwith a CF3 inmeta and a Cl in the para position, rel-
ative to the urea moiety, were the most potent VEGFR-2 inhibitors
in enzymatic assays with IC50 values of 10, 28, 11, 15 and 16 nM,
respectively (Table 1). These values are in line with the most
potent VEGFR-2 inhibitor agents and pending further analysis,
compounds 4d–h can already be considered as potential leads for
new antiangiogenic compounds. This increase of potency in one
order of magnitude with hydrophobic substituents in the terminal
aryl ring provides evidence that the latter in fact occupies the
hydrophobic pocket in a similar fashion to other known type II
inhibitors.
Although compounds 5 have given high IC50 values it was
decided to prepare compounds in this series with substituents
CF3 and/or Cl present in the Sorafenib, but the IC50 values did not
significantly decreased (Table 1).
In order to explain the VEGFR-2 inhibitory activity of com-
pounds 4, we set out to investigate in detail the binding mode of
compounds 4d and 4f and 5a by performing molecular docking
studies.
2.3. Molecular docking simulations
To better understand the structural rational behind the VEGFR-
2 inhibition potency observed for the synthesized compounds,
molecular docking simulations were performed using AutoDock4
software. The VEGFR-2 kinase domain crystal structure with PDB
code: 3VHE was selected because it presented a co-crystallized
inhibitor (compound B, Fig. 1) with the closest structure compared
to the compounds prepared in this work. For a suitable compar-
ison, compounds 5a and compounds 4d and 4f were docked
against the selected structure and then superimposed with the
experimental structure of compound B (Fig. 2A and B). The other
compounds of series 5 were also docked and the obtained docking
poses were a near perfect superimposition to compound 5a dock-
ing pose. So for clearance of representation on Figure 2A only com-
pound 5awas used as it is the simplest, without substitution in the
terminal aryl ring.
For the less potent compound 5a a similar binding mode pat-
tern to compound B was observed (Fig. 2A). In both compounds
the urea moiety forms two H-bonds with the Glu885 carboxyl
group, and the C@O urea group forms a third H-bond with the
backbone N–H of Asp1046. The thieno[3,2-b]pyridine moiety is
docked in adenine pocket with a near perfect superimposition to
the pyrrolo[3,2-d]pyrimidine ring of compound B, and both rings
are positioned in order to form the critical H-bond with the
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the linker region and the terminal aryl ring on the hydrophobic
pocket (Fig. 2A). However a more detailed inspection of compound
5a docking pose gives us some insights on why the S-linker in the
para position is probably less favored compared to the O-linker in
the same position. In fact, in order to accommodate the network of
critical H-bonds and allow a correct pocket occupation of the ring
systems, the S-linker was stretched to a 109.5 angle when the
more stable value for a S-linker angle is approximately 90
(Fig. 2A). The co-crystallized structure of compound B on the other
hand presents a O-linker angle of 115.8 that is closer to the ideal
110 angle.17 This widening of the S-linker is energetically unfavor-
able and probably explain the much lower potency of compound
5a (IC50 = 1166 nM) compared to compound B (IC50 = 6.2 nM). It
is likely that there may be a protein shifting in the active site to
relieve this very high energy situation and the docking presented
in Figure 2A is likely to be an approximation of the actual interac-
tion between compound 5a and the active site.
For the most potent compounds 4d and 4f (IC50 of 10 and
11 nM, respectively) the same superimposition with compound B
is also presented (Fig. 2B). A closer inspection of the docked poses
shows that, due to the presence of the S-linker in themeta position
relative to the urea group, the central aryl ring is placed deeper
inside the linker region, when compared to compound B. The S-lin-
ker sharper angle (100.4) is close to the ideal 90 angle and now
appears to work in favor of increasing VEGFR-2 inhibitory potency
by enabling a more favored occupation of the linker region by the
central aryl ring. In fact this ring is superimposed with the F atom
of compound B, further evidence that this linker region occupation
pattern is possible and probably favored.
The higher inhibition potency of compound 4d with an F atom
in the para position and 4f with a methyl group in the meta posi-
tion, relative to the urea moiety, when compared to compound
4a with no substitution, is also widely observed for other known
type II inhibitors (Fig. 1) and it is due to a better occupation of
the hydrophobic pocket.13–15 This observation further demon-
strates that the predicted docked poses are probably correct.
2.4. Cell culture assays
The best compounds in enzymatic assays (4a–h) against
VEGFR-2 tyrosine kinase domain were examined in cell culture
viability and proliferation assays using HUVECs stimulated by
VEGF. Cell viability was first analyzed by MTS assay (Fig. 3). The
effects of compounds 4a–f at 0.1–10 lM on HUVECs viability are
shown in Figure 3A. Cell viability was reduced by each compound
at a dose-dependent manner, reaching statistical significance at
the concentration of 5.0 lM or higher. The effects of compounds
4g and 4h on HUVECs viability were analyzed. Given the similarity
of the hydrophobic chemical pattern substitution of Sorafenib, this
drug was used as a positive control for compounds 4g and 4h,
these two compounds being used at 1.0–10 lM, the concentrations
established for Sorafenib in cell culture assays (Fig. 3B). Compound
4g significantly reduced the cell viability at 10 lM, while com-
pound 4h did it at 2.5, 5.0 and 10 lM. Nevertheless, they only
affected more than 50% cell viability (4g = 44%, 4h = 26%), revealing
a cytotoxic effect on HUVECs for the highest concentration tested
(10 lM), as Sorafenib (18%). Altogether, these findings reveal that
every compound was able to decrease HUVECs viability. Though,
compounds 4g and 4h presented significant reductions at lower
concentrations.
A proliferation assay was then assessed using the BrdU incorpo-
ration, a thymidine analogue which incorporates into DNA of
dividing cells (Fig. 4). Compounds 4a (R1 = H), 4c (R1 = CN), and
4f (R2 = Me) showed a statistical significant antiproliferative effect
at 1.0 lM (Fig. 4A) without significantly affecting cell viability(Fig. 3A). Remarkably, compounds 4b (R1 = OMe), 4d (R1 = F) and
4e (R2 = F) showed a higher antiproliferative effect, revealing a sta-
tistical significant cell proliferation decrease at 0.5 lM (Fig. 4A)
without affecting cell viability (Fig. 3A). Compounds 4g (R2 = CF3),
4h (R1 = Cl; R2 = CF3) significantly inhibited proliferation of
HUVECs at 2.5 and 5.0 lM, without high cytotoxic effect. Sorafenib
is known to prevent cell growth in endothelial cells.7 Interestingly
enough, compounds 4g and 4h exhibit, thus, a more noteworthy
effect than Sorafenib, which only significantly affected prolifera-
tion of these cells at 5.0 lM (Fig. 4B).
These results showed that all the tested compounds consider-
ably inhibit VEGF-stimulated HUVECs proliferation in a dose-de-
pendent manner at low concentrations.
2.5. Effect on apoptosis
The induction of apoptosis is a therapeutic approach for cancer
treatment. Several anticancer drugs, including some VEGFR-2 inhi-
bitors can promote apoptosis.19 The effect of compounds 4a–h on
cell apoptosis was then evaluated by TUNEL assay (Fig. 5). Concen-
trations of 0.1–1.0 lM of compounds 4a–4f were used in the sub-
sequent assays due to their antiproliferative effect without
cytotoxic effect at these concentrations (Fig. 5A). An increase in
apoptosis was observed when HUVECs were incubated with
increasing concentrations of the tested compounds for 24 h, reach-
ing statistical significance only for 4b–4d at the highest concentra-
tion tested (1.0 lM) in comparison to control. These findings
indicate that besides the effects of these three compounds in
HUVECs proliferation, they also induce apoptosis. Compounds 4a,
4e and 4f increased apoptosis in a dose-dependent manner, but
not with statistical significance (Fig. 5A).
For compounds 4g and 4h, the concentrations selected for this
and the following assays were 2.5 and 5.0 lM since they are the
lowest concentrations of these compounds that have shown an
antiproliferative effect without being cytotoxic to HUVECs
(Figs. 3B and 4B). As shown in Figs. 5B, 4g and h significantly
increase apoptosis at 5.0 lM. Many studies report that Sorafenib
induces apoptosis.19 The findings in this study reveal that com-
pounds 4g and 4h exhibited a higher effect than Sorafenib in
apoptosis.
2.6. Effect on HUVECs migration
Cell migration is an essential feature for endothelial cells in
angiogenesis.20 Therefore, we next examined the effect on the
HUVECs chemotactic motility of the most promising compounds
4d–4h, according to the previous results on HUVECs viability and
proliferation, by wound-healing assay (Fig. 6). The results show
that compounds 4d–4f significantly inhibited VEGF-induced
HUVECs migration in a dose-dependent manner ranging from
0.1 lM to 5.0 lM (Fig. 6A). Treatment with compounds 4g and
4h significantly inhibited HUVECs migration at concentrations of
2.5 lM and 5.0 lM showing a similar effect to Sorafenib (Fig. 6B).
These findings regarding Sorafenib effect in endothelial cell migra-
tion were corroborated by previous studies in the literature.21
Nonetheless, incubation with compound 4h was more effective
than Sorafenib, implying a better inhibitory role in this relevant
angiogenic step.
2.7. Effect on HUVECs tube formation
To elucidate the possible mechanisms of angiogenesis inhibi-
tion, tube formation ability of endothelial cells, which is also a crit-
ical step in the angiogenic process, was assessed in HUVECs. As
shown in Figure 7, HUVECs plated on a Matrigel coated plate
formed capillary-like structures in cells cultured in the absence
Figure 3. Evaluation of the HUVECs viability effects of compounds 4a–h and Sorafenib on VEGF-stimulated HUVECs by MTS assay. (A) HUVECs viability upon treatment with
compounds 4a–f at concentrations of 0.1–10 lM. (B) HUVECs viability upon treatment with compounds 4g, 4h and Sorafenib at 1.0–10 lM. Results were obtained after 24 h,
and are expressed as percentage of control (0.1% DMSO with 60 ng/mL VEGF) as means ± SEM of at least three independent experiments, performed in triplicate. *p <0.05
versus control.
Figure 4. Effect of compounds 4a–4h and Sorafenib on VEGF-induced HUVECs proliferation assessed by BrdU incorporation assay. (A) HUVECs proliferation upon treatment
with compounds 4a–4f at concentrations of 0.1–10 lM. (B) HUVECs proliferation upon treatment with compounds 4g, 4h and Sorafenib at concentrations of 1.0–10 lM.
Results were obtained after 24 h incubation, and are expressed as percentage of control (0.1% DMSO with 60 ng/mL VEGF) as means ± SEM of at least three independent
experiments, performed in triplicate. *p <0.05 versus control.
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was observed whenever cells were incubated with compounds
4d–4f at concentrations of 0.5–5.0 lM, in a dose-dependent man-
ner (Fig. 7A). In the presence of compounds 4g, 4h or Sorafenib at
concentrations of 2.5 and 5 lM, tube formation of HUVECs was sig-
nificantly reduced (Fig. 7B), except for 4g at 2.5 lM. This assay is a
hallmark of angiogenesis evaluation in vitro. Interestingly, preven-
tion of this process was also accomplished by every compoundtested in the present study in a significant manner, implying thus,
the important antiangiogenic role of these molecules.
2.8. Effect on VEGFR-2 phosphorylation
The results presented herein were obtained in VEGF stimulated
HUVECs cultures, implying that the compounds analyzed were
able to exert their effects by interfering with VEGF signalling
Figure 5. Effect of compounds 4a–4h and Sorafenib on apoptosis assessed by TUNEL assay. (A) HUVEC apoptosis upon treatment with compounds 4a–4f at concentrations of
0.1–1.0 lM. (B) HUVEC apoptosis upon treatment with compounds 4g, 4h and Sorafenib at concentrations of 2.5 and 5.0 lM. Bars represent the percentage of apoptotic cells
evaluated by ratio between TUNEL-stained cells and DAPI-stained nuclei in every culture. Results were obtained after 24 h, and are expressed as mean ± SEM of at least three
independent experiments. *p <0.05 versus control.
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total and phosphorylated (active) VEGFR-2 was performed. At
1.0 lM compounds 4a, 4b and 4d–4f significantly decreased the
active form of VEGFR-2 (Fig. 8A–D) (*p <0.05 vs control). Moreover,
compounds 4g and 4h, at concentrations of 2.5 and 5.0 lM,
significantly decreased VEGFR-2 phosphorylation, presenting a
better effect than Sorafenib (Fig. 8E and F).
VEGF signalling pathway through the VEGFR-2 tyrosine kinase
phosphorylation displays a crucial role in angiogenesis, namely,
enhancing endothelial cell survival, proliferation and migration.22
Many other signalling pathways are involved in angiogenesis, nev-
ertheless, VEGF signalling, an angiogenic surrogate pathway, which
is involved in the whole multistep process, from cell proliferation,
migration, invasiveness capacity, anastomosis, ending up in the
assembly of newly formed vascular structures. Therefore, we
believe that inhibiting this pathway is an effective approach
against angiogenesis.
3. Conclusion
In conclusion the synthesis of new 1-aryl-3-[2-, 3- or 4-(thieno-
[3,2-b]pyridin-7-ylthio)phenyl]ureas 3, 4 and 5 in overall good
yields is reported. Compounds 4, with the arylurea in the meta
position relative to the S-linker, showed to be the most potent
phosphorylation tyrosine kinase VEGFR-2 inhibitors, presenting
IC50 values between 10 and 206 lM in enzymatic assays, depend-
ing on the substituents on the terminal phenyl ring. To better
understand these results, molecular docking simulations were per-
formed. The predicted docked poses were analyzed in detail and aplausible explanation for compounds 4 and in particularly for 4d
and 4f potency (10 and 11 nM) was obtained based on the simul-
taneous presence of a S-linker and the arylurea moiety in the meta
position as a new substitution pattern for the type II VEGFR-2 inhi-
bitors. The importance of hydrophobic substituents in 4d and 4f (F
and Me, respectively) in the terminal phenyl ring is also high-
lighted. These chemical features place the thieno[3,2-b]pyridine
and the terminal aryl ring in close superimposition to a pyrrolo
[3,2-d]pyrimidine derivative, type II co-crystallized VEGFR-2
ligand. Compounds 4g an 4h with pattern substitution closer to
Sorafenib showed also low IC50 values (15 and 16 nM).
Our results showed that compounds 4 affect various steps of
angiogenesis including endothelial cell proliferation, apoptosis,
migration and capillary structure formation in a dose dependent
manner.
In the present study we found that compounds 4 significantly
block the tyrosine kinase phosphorylation of VEGFR-2, as observed
by Western blotting in vitro, suggesting these compounds as
potent VEGFR-2 inhibitors.
As far as our knowledge the S-linker in the meta position rela-
tive to the urea moiety constitutes a new substitution pattern that
has not been disclosed in other known type II VEGFR-2 inhibitors.
This can thus be regarded as an interesting feature for the syn-
thesis of new compounds with higher VEGFR-2 inhibitory activity
and also for other scaffolds exploring the same VEGFR-2 binding
conformation.
Although future studies, namely using animal models, are cru-
cial, overall, our findings support the hypothesis that all these
molecules are potent antiangiogenic agents.
Figure 6. Effect of compounds 4d–4h on HUVECs migration (wound-healing assay) after incubation during 24 h. Representative fields were photographed, 100
magnification. The graphics shows the quantitative effect of compounds 4d–4f (A), 4g–4h and Sorafenib (B) on VEGF-induced HUVECs motility. Data presented the
percentage of control, as mean ± SEM of three independent experiments. *p <0.001 versus control.
Figure 7. Effect of compounds 4d–4h on VEGF-induced capillary-like tube formation of HUVEC through Matrigel in 24 h. Representative fields were photographed, 100
magnification. Bars show the quantitative effect of compounds 4d–4f (A), 4g–4h and Sorafenib (B) on VEGF-induced HUVEC tube formation. Data were presented as the
percentage of control, as mean ± SEM of three independent experiments. *p <0.001 versus control.
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Figure 8. (A, C and E) Evaluation of phosphorylated and total VEGFR-2 expression in HUVECs after incubation with compounds 4a–4h, by Western blotting. Representative
bands obtained after immunostaining are shown. (B, D and F) Quantification by densitometry and mean relative intensity by comparison of the relative intensity of activated
VEGFR-2 after normalization with total VEGFR-2 intensity. Data presented as mean ± SEM of two independent experiments. *p <0.05 versus control.
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4.1. Synthesis
Melting points (C) were determined in a Stuart SMP3 and are
uncorrected. 1H and 13C NMR spectra were recorded on a Varian
Unity Plus at 300 and 75.4 MHz, respectively or on a Bruker Avance
III at 400 and 100.6 MHz, respectively, and the chemical shifts were
quoted in parts per million (ppm) referenced to the appropriate
non-deuterated solvent peak relative to 0.0 ppm for tetramethylsi-
lane. Two dimensional 1H–13C correlations were performed to
attribute some signals. Mass spectra (MS) EI-TOF or ESI-TOF and
HRMS on the M+ or on the [M+H]+ were performed by the mass
spectrometry service of the University of Vigo, C.A.C.T.I., Spain
and the low resolution MS ESI of compounds 4g, 4h, 5d and 5e
were performed by direct injection on a ThermoFinigan spec-
trophotometer LC–MS. Elemental Analysis was performed on a
LECO CHNS 932 Elemental Analyser. The compounds yielded data
consistent with a purity of at least 95% as compared with the the-
oretical values. The reactions were monitored by thin layer chro-
matography (TLC) using Macherey-Nagel pre-coated aluminium
silica gel 60 sheets (0.20 mm) with UV254 indicator. Column chro-
matography was performed on Panreac, Silica Gel 60, 230–400
mesh. Ether refers to diethylether. Petroleum ether refers to theboiling range 40–60 C. Aminothiophenols were purchased from
Sigma–Aldrich with purity P96%.
4.1.1. General synthesis procedure for compounds 2a–c
In a flask with DMF (5 mL), compound 1, the aminothiophenol
(1 equiv) and K2CO3 (4 equiv) were heated at 140 C for 2 h. After
cooling water (5 mL) and ethyl acetate (5 mL) were added. The
phases were separated and the aqueous phase was extracted with
more ethyl acetate (2  5 mL). The organic phase was dried
(MgSO4) and filtered. The solvent was evaporated under reduced
pressure giving an oil which was submitted to column
chromatography.
4.1.1.1. 2-(Thieno[3,2-b]pyridin-7-ylthio)aniline (2a). Compound
1 (150 mg, 0.880 mmol) and 2-aminothiophenol (110 mg) and the
general procedure was followed. Column chromatography using
70% ether/petroleum ether gave compound 2a as an oil (180 mg,
80%). 1H NMR (DMSO-d6, 300 MHz): d 5.54 (br s, 2H, NH2), 6.57
(d, J = 5.2 Hz, 1H, 60-H), 6.62–6.67 (m, 1H, 4-H), 6.87 (dd, J = 8.4
and 1.5 Hz, 1H, 6-H), 7.25–7.30 (m, 1H, 5-H), 7.37 (dd, J = 8.4 and
1.5 Hz, 1H, 3-H), 7.57 (d, J = 5.6 Hz, 1H, HetArH), 8.14 (d,
J = 5.6 Hz, 1H, HetArH), 8.42 (d, J = 5.2 Hz, 1H, 50-H) ppm. 13C
NMR (DMSO-d6, 75.4 MHz,): d 107.2 (C), 114.0 (60-CH), 115.3
(6-CH), 116.9 (4-CH), 124.9 (CH), 129.3 (C), 131.6 (CH), 132.3
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ppm. MS (EI- TOF) m/z (%): 258.03 (M+, 100). HRMS (EI-TOF): calcd
for C13H10N2S2 [M+] 258.0285, found 258.0284.
4.1.1.2. 3-(Thieno[3,2-b]pyridin-7-ylthio)aniline (2b). Compound
1 (200 mg, 1.20 mmol) and 3-aminothiophenol (125 mg) and the
general procedure was followed. Column chromatography using
45% ether/petroleum ether gave compound 2b as a yellow solid
(280 mg, 90%). Mp 106–107 C. 1H NMR (DMSO-d6, 400 MHz): d
5.40 (br s, 2H, NH2), 6.69–6.71 (m, 2H, 4 and 6-H), 6.75–6.76 (m,
1H, 2-H), 6.87 (d, J = 4.8 Hz, 1H, 60-H), 7.14 (apparent t, J = 8 Hz,
1H, 5-H), 7.58 (d, J = 5.6 Hz, 1H, HetArH), 8.14 (d, J = 5.6 Hz, 1H,
HetArH), 8.49 (d, J = 4.8 Hz, 1H, 50-H) ppm. 13C MNR (DMSO-d6,
100.6 MHz): d 115.2 (CH), 116.0 (60-CH), 118.7 (2-CH), 121.0
(CH), 125.0 (CH), 128.1 (C), 130.3 (C), 130.5 (5-CH), 131.8 (CH),
142.8 (C), 147.4 (50-CH), 150.3 (C), 155.7 (C) ppm. MS (ESI- TOF)
m/z (%): 259.03 (M++H, 100). HRMS (ESI-TOF): calcd for
C13H11N2S2 [M++H] 259.0358, found 259.0358. Anal. Calcd for
C13H10N2S2: C, 60.43; H, 3.90; N, 10.84; S, 24.82. Found: C, 60.57;
H, 4.01; N, 11.02; S, 24.42.
4.1.1.3. 4-(Thieno[3,2-b]pyridin-7-ylthio)aniline (2c). Compound
1 (150 mg, 0.880 mmol) and 4-aminothiophenol (110 mg) was
treated according to the general procedure. Column chromatogra-
phy using 40% ether/petroleum ether gave compound 2c as a
yellow solid (210 mg, 90%). Mp 215–216 C. 1H NMR (CDCl3,
400 MHz): d 3.85 (br s, 2H, NH2), 6.70 (d, J = 5.2 Hz, 1H, 60-H),
6.76 (d, J = 8.4 Hz, 2H, 2 and 6-H), 7.40 (d, J = 8.4 Hz, 2H, 3 and 5-
H), 7.64 (d, J = 5.6 Hz, 1H, HetArH), 7.78 (d, J = 5.6 Hz, 1H, HetArH),
8.39 (d, J = 5.2 Hz, 1H, 50-H) ppm. 13C NMR (CDCl3, 100.6 MHz): d
114.5 (60-CH), 116.0 (2 and 6-CH), 124.2 (CH), 130.2 (C), 131.1
(CH), 135.8 (C), 136.4 (C), 137.4 (3 and 5-CH), 145.2 (50-CH),
148.7 (C), 153.6 (C) ppm. MS (EI- TOF) m/z (%): 258.03 (M+, 100).
HRMS (EI-TOF): calcd for C13H10N2S2 [M+] 258.0285, found
258.0289. Anal. Calcd for C13H10N2S2: C, 60.43; H, 3.90; N, 10.84;
S, 24.82. Found: C, 60.59; H, 4.11; N, 10.90; S, 24.40.
4.1.2. General procedure for the synthesis of 1,3-diarylureas 3–5
Compounds 2a–c and different arylisocyanates (1 equiv) in
6 mL CH2Cl2/THF (1:1) were left stirring at room temperature for
12 h. If a precipitate does not come out after this time, hexane
(3–5 mL) was added to the mixture to precipitate the product. This
was filtered under vacuum to give the corresponding 1,3-
diarylureas.
4.1.2.1. 1-Phenyl-3-[2-(thieno[3,2-b]pyridin-7-ylthio)phenyl]-
urea (3a). From compound 2a (100 mg, 0.390 mmol) and
phenylisocyanate (50.0 mg) compound 3a was isolated as a green
solid (95.0 mg, 65%). Mp 198–199 C. 1H NMR (DMSO-d6,
300 MHz): d 6.56 (d, 1H, J = 4.8 Hz), 6.92–6.98 (m, 1H), 7.12–7.18
(m, 1H), 7.24–7.29 (m, 2H), 7.37–7.46 (m, 2H), 7.54–7.63 (m,
3H), 8.18 (d, 1H, J = 5.6 Hz), 8.28–8.31 (m, 1H), 8.45 (d, 1H,
J = 4.8 Hz), 8.49 (br s, 1H, NH), 9.36 (br s, 1H, NH) ppm. 13C NMR
(DMSO-d6, 75.4 MHz): d 114.3 (CH), 115.3 (C), 118.2 (CH), 118.3
(2  CH), 121.3 (CH), 122.1 (CH), 123.6 (CH), 125.0 (CH), 128.8
(2  CH), 129.5 (C), 131.9 (CH), 137.3 (CH), 139.3 (C), 142.3 (C),
142.4 (C), 147.5 (CH), 152.2 (C), 155.8 (C) ppm. MS (ESI-TOF) m/z
(%): 378.07 (M++H, 100) HRMS (ESI-TOF): calcd for C20H16N3OS2
[M++H] 378.0729, found 378.0723. Anal. Calcd for C20H15N3OS2:
C, 63.64; H, 4.01; N, 11.13; S, 16.99. Found: C, 63.83; H, 4.13; N,
10.83; S, 16.60.
4.1.2.2. 1-(4-Methoxyphenyl)-3-[2-(thieno[3,2-b]pyridin-7-ylthio)-
phenyl]urea (3b). From compound 2a (100 mg, 0.390 mmol)
and 4-methoxyphenylisocyanate (83.0 mg), compound 3b wasisolated as a green solid (100 mg, 63%). Mp 198–199 C. 1H NMR
(DMSO-d6, 400 MHz): d 3.68 (s, 3H, OMe), 6.55 (d, J = 5.2 Hz, 1H),
6.82 (d, J = 9.2 Hz, 2H), 7.13 (m, 1H), 7.28 (d, J = 9.2 Hz, 2H),
7.53–7.61 (m, 3H), 8.18 (d, J = 5.6 Hz, 1H), 8.31 (dd, J = 8.4 and
1.2 Hz, 1H), 8.38 (br s, 1H, NH), 8.45 (d, J = 5.2 Hz, 1H), 9.17 (br s,
1H, NH) ppm. 13C NMR (DMSO-d6, 100.6 MHz): d 55.1 (OMe),
114.0 (2  CH), 114.2 (CH), 114.9 (C), 120.1 (2  CH), 121.0 (CH),
123.3 (CH), 125.0 (CH), 129.4 (C), 131.8 (CH), 131.9 (CH), 132.2
(C), 137.2 (CH), 142.3 (C), 142.5 (C), 147.5 (CH), 152.3 (C), 154.6
(C), 155.8 (C) ppm. MS (ESI-TOF) m/z (%): 408.08 (M++H, 100).
HRMS (ESI-TOF): calcd for C21H18N3O2S2 [M++H] 408.0835, found
408.0832. Anal. Calcd for C21H17N3O2S2: C, 61.89; H, 4.20; N,
10.31; S, 15.74. Found: C, 62.01; H, 4.05; N, 11.00; S, 15.33.
4.1.2.3. 1-(4-Cyanophenyl)-3-[2-(thieno[3,2-b]piridin-7-ylthio)-
phenyl]urea (3c). From compound 2a (60.0 mg, 0.230 mmol)
and 4-cyanophenylisocyanate (37.0 mg) compound 3c was iso-
lated as a green solid (60.0 mg, 65%). Mp 208–209 C. 1H NMR
(DMSO-d6, 300 MHz): d 6.57 (d, J = 5.2 Hz, 1H), 7.17–7.22 (m,
1H), 7.58–7.60 (m, 5H), 7.68 (d, J = 9.2 Hz, 2H), 8.17 (d, J = 5.6 Hz,
1H), 8.24 (dd, J = 8.4 and 1.5 Hz, 1H), 8.45 (d, J = 5.2 Hz, 1H), 8.65
(br s, 1H, NH), 9.80 (br s, 1H, NH) ppm. 13C NMR (DMSO-d6,
75.4 MHz): d 103.6 (C), 114.5 (CH), 116.3 (C), 118.1 (2  CH),
119.2 (C), 121.7 (CH), 124.3 (CH), 125.0 (CH), 129.6 (C), 131.9
(CH), 131.9 (CH), 133.3 (2  CH), 137.2 (CH), 141.7 (C), 142.1 (C),
143.8 (C), 147.5 (CH), 151.9 (C), 155.8 (C) ppm. MS (ESI-TOF) m/z
(%): 403.07 (M++H, 100). HRMS (ESI-TOF): calcd for C21H15N4OS2
[M++H] 403.0682, found 403.0689. Anal. Calcd for C21H14N4OS2:
C, 62.67; H, 3.51; N, 13.92; S, 15.93. Found: C, 62.95; H, 3.32; N,
14.12; S, 15.51.
4.1.2.4. 1-Phenyl-3-[3-(thieno[3,2-b]pyridin-7-ylthio)phenyl]-
urea (4a). From compound 2b (80.0 mg, 0.300 mmol) and
phenylisocyanate (36.0 mg) compound 4a was isolated as a yellow
solid (70 mg, 63%). Mp 94–95 C. 1H NMR (DMSO-d6, 400 MHz): d
6.95 (d, J = 5.2 Hz, 1H), 6.96–6.98 (m, 1H), 7.17–7.20 (m, 1H),
7.24–7.28 (m, 2H), 7.39–7.44 (m, 3H), 7.49–7.52 (m, 1H), 7.60 (d,
J = 5.6 Hz, 1H), 7.78–7.79 (m, 1H), 8.16 (d, J = 5.6 Hz, 1H), 8.52 (d,
J = 5.2 Hz, 1H), 8.70 (br s, 1H, NH), 8.90 (br s, 1H, NH) ppm. 13C
NMR (DMSO-d6, 100.6 MHz): d 116.5 (CH), 118.4 (2  CH), 119.3
(CH), 122.1 (CH), 122.8 (CH), 125.0 (CH), 127.0 (CH), 128.7
(2  CH), 128.8 (C), 130.5 (CH), 130.8 (C), 132.0 (CH), 139.4 (C),
141.2 (C), 141.9 (C), 147.6 (CH), 152.4 (C), 155.9 (C) ppm. MS
(ESI-TOF) m/z (%): 378.07 (M++H, 100) HRMS (ESI-TOF): calcd for
C20H16N3OS2 [M++H] 378.0729, found 378.0728. Anal. Calcd for
C20H15N3OS2: C, 63.64; H, 4.01; N, 11.13; S, 16.99. Found: C,
63.86; H, 3.80; N, 11.33; S, 16.59.
4.1.2.5. 1-(4-Methoxyphenyl)-3-[3-(thieno[3,2-b]pyridin-7-ylthio)-
phenyl]urea (4b). From compound 2b (100 mg, 0.390 mmol)
and 4-methoxyphenylisocyanate (58.0 mg), compound 4b was iso-
lated as a yellow solid (100 mg, 64%). Mp 132–133 C. 1H NMR
(DMSO-d6, 400 MHz): d 3.69 (s, 3H, OMe), 6.84 (d, J = 8.8 Hz, 2H),
6.92 (d, J = 4.8 Hz, 1H), 7.16–7.18 (m, 1H), 7.31 (d, J = 8.8 Hz, 2H),
7.30–7.33 (m, 1H), 7.48–7.51 (m, 1H), 7.60 (d, J = 5.6 Hz, 1H),
7.77–7.78 (m, 1H), 8.16 (d, J = 5.6 Hz, 1H), 8.50 (br s, 1H, NH),
8.52 (d, J = 4.8 Hz, 1H), 8.80 (br s, 1H, NH) ppm. 13C NMR (DMSO-
d6, 100.6 MHz): d 55.1 (OMe), 113.9 (2  CH), 116.5 (CH), 119.2
(CH), 120.3 (2  CH), 122.7 (CH), 125.0 (CH), 126.9 (CH), 128.8
(C), 130.4 (CH), 130.7 (C), 132.0 (CH), 132.3 (C), 141.4 (C), 141.9
(C), 147.6 (CH), 152.6 (C), 154.6 (C), 155.9 (C) ppm. MS (ESI-TOF)
m/z (%): 408.08 (M++H, 100). HRMS (ESI-TOF): calcd for C21H18N3-
O2S2 [M++H] 408.0835, found 408.0833. Anal. Calcd for C21H17N3-
O2S2: C, 61.89; H, 4.20; N, 10.31; S, 15.74. Found: C, 62.20; H,
4.45; N, 10.02; S, 15.35.
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phenyl]urea (4c). From compound 2b (60.0 mg, 0.230 mmol)
and 4-cyanophenylisocyanate (35.0 mg), compound 4c was iso-
lated as a yellow solid (65.0 mg, 65%). Mp 168–169 C. 1H NMR
(DMSO-d6, 400 MHz): d 6.95 (d, J = 5.2 Hz, 1H), 7.21–7.24 (m,
1H), 7.42–7.46 (m, 1H), 7.52–7.55 (m, 1H), 7.59 (d, J = 5.6 Hz,
1H), 7.60 (d, J = 8.8 Hz, 2H), 7.71 (d, J = 8.8 Hz, 2H), 7.76–7.77 (m,
1H), 8.16 (d, J = 5.6 Hz, 1H), 8.53 (d, J = 5.2 Hz, 1H), 9.07 (br s, 1H,
NH), 9.23 (br s, 1H, NH) ppm. 13C NMR (DMSO-d6, 100.6 MHz): d
103.5 (C), 116.7 (CH), 118.2 (2  CH), 119.2 (C), 119.6 (CH), 123.0
(CH), 125.0 (CH), 127.5 (CH), 129.0 (C), 130.5 (CH), 130.9 (C),
132.0 (CH), 133.2 (2  CH), 140.7 (C), 141.6 (C), 143.9 (C), 147.6
(CH), 152.0 (C), 155.9 (C) ppm. MS (ESI- TOF) m/z (%): 403.07
(M++H, 100) HRMS (ESI-TOF): calcd for C21H15N4OS2 [M++H]
403.0682, found 403.0680. Anal. Calcd for C21H14N4OS2: C, 62.67;
H, 3.51; N, 13.92; S, 15.93. Found: C, 62.37; H, 3.80; N, 14.13; S,
15.52.
4.1.2.7. 1-(4-Fluorophenyl)-3-[3-(thieno[3,2-b]pyridin-7-ylthio]-
phenyl)urea (4d). From compound 2b (60.0 mg, 0.230 mmol)
and 4-fluorophenylisocyanate (35.0 mg), compound 4d was iso-
lated as a white solid (65.0 mg, 71%). Mp 140–141 C. 1H NMR
(DMSO-d6, 400 MHz): d 6.93 (1H, d, J = 5.2 Hz), 7.07–7.12 (m,
2H), 7.18–7.20 (m, 1H), 7.39–7.44 (m, 3H), 7.50–7.52 (m, 1H),
7.60 (d, J = 5.6 Hz, 1H), 7.76–7.77 (m, 1H), 8.16 (d, J = 5.6 Hz, 1H),
8.52 (d, J = 5.2 Hz, 1H), 8.73 (br s, 1H, NH), 8.89 (br s, 1H, NH)
ppm. 13C NMR (DMSO-d6, 100.6 MHz): d 115.3 (d, J = 22 Hz,
2  CH), 116.6 (CH), 119.4 (CH), 120.2 (d, J = 7.0 Hz, 2  CH),
122.8 (CH), 125.1 (CH), 127.1 (CH), 128.9 (C), 130.5 (CH), 130.8
(C), 132.0 (CH), 135.7 (C), 141.2 (C), 141.9 (C), 147.6 (CH), 152.5
(C), 155.9 (C), 157.5 (d, J = 238 Hz, CF) ppm. MS (ESI-TOF) m/z
(%): 396.06 (M++H, 100). HRMS (ESI-TOF): calcd for C20H15FN3OS2
[M++H] 396.0635, found 396.0634. Anal. Calcd for C20H14FN3OS2:
C, 60.74; H, 3.57; N, 10.63; S, 16.22. Found: C, 61.01; H, 3.28; N,
10.35; S, 15.81.
4.1.2.8. 1-(3-Fluorophenyl)-3-[3-(thieno[3,2-b]pyridin-7-ylthio)-
phenyl]urea (4e). From compound 2b (60.0 mg, 0.230 mmol)
and 3-fluorophenylisocyanate (35.0 mg) compound 4e was iso-
lated as a white solid (63.0 mg, 69%). Mp 104–105 C. 1H NMR
(DMSO-d6, 400 MHz): d 6.77–6.78 (m, 1H), 6.93 (d, 1H,
J = 5.2 Hz), 7.09–7.11 (m, 2H), 7.19–7.20 (m, 1H), 7.21–7.29 (m,
1H), 7.41–7.52 (m, 2H), 7.53–7.54 (m, 1H), 7.60 (d, 1H,
J = 5.6 Hz), 7.7–7.7 (m, 1H), 8.16 (d, 1H, J = 5.6 Hz), 8.52 (d, 1H,
J = 5.2 Hz), 8.94 (br s, 1H, NH), 8.96 (br s, 1H, NH) ppm. 13C NMR
(DMSO-d6, 100.6 MHz): d 105.0 (d, J = 26 Hz, CH), 108.4 (d,
J = 21 Hz, CH), 114.1 (d, J = 2 Hz, CH), 116.6 (CH), 119.5 (CH),
122.9 (CH), 125.0 (CH), 127.3 (CH), 128.9 (C), 130.3 (d, J = 9.6 Hz,
CH), 130.5 (CH), 130.8 (C), 132.0 (CH), 140.9 (C), 141.3 (d,
J = 11.5 Hz, C), 141.8 (C), 147.6 (CH), 152.2 (C), 155.9 (C), 162.3
(d, J = 240 Hz, CF) ppm. MS (ESI-TOF) m/z (%): 396.06 (M++H,
100). HRMS (ESI-TOF): calcd for C20H15FN3OS2 [M++H] 396.0635,
found 396.0627. Anal. Calcd for C20H14FN3OS2: C, 60.74; H, 3.57;
N, 10.63; S, 16.22. Found: C, 61.03; H, 3.33; N, 10.30; S, 15.82.
4.1.2.9. 1-[3-(Thieno[3,2-b]pyridin-7-ylthio)phenyl]-3-m-toly-
lurea (4f). From compound 2b (60.0 mg, 0.230 mmol) and
m-tolylisocyanate (35.0 mg) compound 4f was isolated as a white
solid (65.0 mg, 72%). Mp 157–158 C. 1H NMR (DMSO-d6,
400 MHz): d 2.25 (s, 3H, CH3), 6.77–6.79 (m, 1H), 6.93 (d, 1H,
J = 4.8 Hz), 7.11–7.20 (m, 3H), 7.26–7.29 (m, 1H), 7.39–7.44 (m,
1H), 7.49–7.51 (m, 1H), 7.60 (d, 1H, J = 5.6 Hz), 7.79–7.80 (m,
1H), 8.16 (d, 1H, J = 5.6 Hz), 8.52 (d, 1H, J = 4.8 Hz), 8.61 (br s, 1H,
NH), 8.87 (br s 1H, NH) ppm. 13C NMR (DMSO-d6, 100.6 MHz): d
21.2 (CH3), 115.5 (CH), 116.5 (CH), 118.9 (CH), 119.3 (CH), 122.8
(CH), 122.8 (CH), 125.0 (CH), 127.0 (CH), 128.6 (CH), 128.8 (C),130.5 (CH), 132.0 (CH), 137.9 (C), 139.3 (C), 139.6 (C), 141.2 (C),
141.9 (C), 147.6 (CH), 152.3 (C), 155.9 (C) ppm. MS (ESI- TOF)
m/z (%): 392.09 (M++H, 100). HRMS (ESI-TOF): calcd for
C21H18N3OS2 [M++H] 392.0886, found 392.0894. Anal. Calcd
for C21H17N3OS2: C, 64.42; H, 4.38; N, 10.73; S, 16.38%. Found:
C 64.24; H, 4.26; N, 11.03; S, 15.97%.
4.1.2.10. 1-[3-(Trifluoromethyl)phenyl]-3-[3-(thieno[3,2b]pyri-
din-7-ylthio)phenyl]urea (4g). From 3-(thieno[3,2-b]pyridine-
7-ylthio)aniline (100 mg, 0.387 mmol) and 3-(trifluoromethyl)-
phenylisocyanate (72.4 mg, 53.4 lL, 0.387 mmol) compound 4g
was isolated as a beige solid (86.0 mg, 50%) Mp 138–140 C. 1H
NMR (DMSO-d6, 400 MHz): 6.93 (d, J = 4.8 Hz, 6000-H), 7.23 (br d,
1H), 7.30 (br d, 1H), 7.42–7.57 (m, 4H), 7.60 (d, J = 5.6 Hz, 1H),
7.80 (br s, 1H,), 7.96 (br s, 1H,), 8.16 (d, J = 5.6 Hz, 1H), 8.53 (d,
J = 4.8 Hz, 5000-H), 9.03 (s, NH), 9.09 (s, NH). 13C NMR (DMSO-d6,
100.6 MHz): 114.30 (q, J = 3.9 Hz, 20-CH), 116.53 (6000-CH), 118.30
(q, J = 3.9 Hz, 40-CH), 119.66 (CH), 122.00 (CH), 123.10 (CH),
123.8 (q, J = 273.0 Hz, CF3), 125.0 (CH), 127.4 (CH), 128.86 (C),
129.5 (q, J = 31 Hz, CCF3), 130.0 (CH), 130.5 (CH), 130.78 (C),
132.1 (CH), 140.30 (C), 140.90 (C), 142.00 (C), 147.50 (5000-CH),
152.39 (C), 155.79 (C) ppm. MS (ESI): 446.25 (M++H, 100). Anal.
Calcd for C21H14F3N3OS2: C, 56.62; H, 3.17; N, 9.43; S, 14.40%.
Found: C 56.31; H, 3.28; N, 9.70; S, 14.80%.
4.1.2.11. 1-[4-Chloro-3-(trifluoromethyl)phenyl]-3-[3-(thieno-
[3,2-b]pyridin-7-ylthio)phenyl]urea (4h). From 3-(thieno-
[3,2-b]pyridine-7-ylthio)aniline (78.6 mg, 0.304 mmol) and
4-chloro-3-(trifluoromethyl)isocyanate (67.4 mg, 0.304 mmol)
compound 4h was isolated as a beige solid (87.6 mg, 60%). Mp
196–198 C. 1H NMR (DMSO-d6, 400 MHz): 6.93 (d, J = 4.8 Hz,
6000-H), 7.23 (br d, 1H), 7.43 (apparent t, J = 8.0 Hz, 400-H), 7.54–
7.64 (4H, m), 7.77 (apparent t, J = 2.0 Hz, 200-H), 8.06 (d, J = 2.4 Hz,
20-H), 8.16 (d, J = 5.2 Hz, 1H), 8.52 (d, J = 4.8 Hz, 5000-H), 9.07 (s,
NH), 9.20 (s, NH). 13C NMR (DMSO-d6, 100.6 MHz): 116.6
(6000-CH), 116.9 (q, J = 6.0 Hz, 20-CH), 119.7 (CH), 122.5 (C), 122.8
(q, J = 272.6 Hz, CF3), 123.2 (CH), 123.3 (CH), 125.0 (CH), 126.7 (q,
J = 30.0 Hz, CCF3), 127.5 (CH), 128.9 (C), 130.50 (400-CH), 130.8 (C),
132.0 (CH), 132.1 (CH), 139.1 (C), 140.8 (C), 141.9 (C), 147.6 (5000-
CH), 152.3 (C), 155.9 (C) ppm. MS (ESI): m/z (%) 480.17 (M+ 35Cl
+H, 100), 482.17 (M+ 37Cl+H, 30) Anal. Calcd for C21H13ClF3N3OS2:
C, 52.55; H, 2.73; N, 8.76; S, 13.36%. Found: C 52.24; H, 2.74; N,
8.62; S, 13.27%.
4.1.2.12. 1-Phenyl-3-[4-(thieno[3,2-b]pyridin-7-ylthio)phenyl]-
urea (5a). From compound 2c (100 mg, 0.370 mmol) and
phenylisocyanate (44.0 mg) compound 5a was isolated as a yellow
solid (90.0 mg, 65%). Mp 92–93 C. 1H NMR (DMSO-d6, 300 MHz): d
6.73 (d, J = 5.2 Hz, 1H), 6.96–7.01 (m, 1H), 7.26–7.29 (m, 2H), 7.44–
7.47 (m, 2H), 7.55–7.62 (m, 5H), 8.15 (d, J = 5.4 Hz, 1H), 8.51 (br s,
1H), 8.77 (br s, 1H, NH), 9.02 (br s, NH) ppm. 13C NMR (DMSO-d6,
75.4 MHz): d 115.1 (CH), 118.4 (2  CH), 118.8 (C), 119.3
(2  CH), 122.2 (CH), 125.0 (CH), 128.8 (2  CH), 131.7 (CH),
136.2 (2  CH), 139.4 (C), 141.9 (C), 143.8 (C), 147.4 (CH), 152.3
(C), 155.6 (C) ppm. MS (ESI- TOF) m/z (%): 378.07 (M++H, 100).
HRMS (ESI-TOF): calcd for C20H16N3OS2 [M++H] 378.0729, found
378.0720. Anal. Calcd for C20H15N3OS2: C, 63.64; H, 4.01; N,
11.13; S, 16.99%. Found: C 63.82; H, 4.15; N, 10.92; S, 16.59%.
4.1.2.13. 1-(4-Methoxyphenyl)-3-[4-(thieno[3,2-b]pyridin-7-
ylthio)phenyl]urea (5b). From compound 2c (60.0 mg,
0.230 mmol) and 4-methoxyphenylisocyanate (35.0 mg,) com-
pound 5b was isolated as a yellow solid (65.0 mg, 70%). Mp 195–
196 C. 1H NMR (DMSO-d6, 400 MHz): d 3.71 (s, 3H, OMe), 6.72
(d, J = 5.2 Hz, 1H), 6.87 (d, J = 8.8 Hz, 2H), 7.36 (d, J = 8.8 Hz, 2H),
7.55 (d, J = 8.8 Hz, 2H), 7.58 (d, J = 5.6 Hz), 7.61 (d, J = 8.8 Hz, 2H),
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8.93 (br s, 1H, NH) ppm. 13 C NMR (DMSO-d6, 100.6 MHz): d 55.2
(OMe), 114.1 (2  CH), 114.9 (CH), 118.5 (C), 119.2 (2  CH),
120.2 (2  CH), 124.9 (CH), 129.4 (C), 131.7 (CH), 132.3 (C), 136.2
(2  CH), 142.1 (C), 143.9 (C), 147.4 (CH), 152.5 (C), 154.7 (C),
155.7 (C) ppm. MS (ESI- TOF) m/z (%): 408.08 (M++H, 100). HRMS
(ESI-TOF): calcd for C21H18N3O2S2 [M++H] 408.0835, found
408.0833. Anal. Calcd for C21H17N3O2S2: C, 61.89; H, 4.20; N,
10.31; S, 15.74%. Found: C 62.01; H, 3.94; N, 10.60; S, 15.32%.
4.1.2.14. 1-(4-Cyanophenyl)-3-[4-(thieno[3,2-b]pyridin-7-ylthio)-
phenyl]urea (5c). From compound 2c (120 mg, 0.460 mmol) and
4-cyanophenylisocyanate (66.0 mg), compound 5c was isolated as
a yellow solid (120 mg, 65%). Mp 154–155 C. 1H NMR (DMSO-d6,
400 MHz): d 6.74 (d, J = 5.2 Hz, 1H), 7.57 (d, J = 5.6 Hz, 1H), 7.58
(d, J = 8.8 Hz, 2H), 7.63–7.65 (m, 4H), 7.74 (d, J = 8.8 Hz, 2H), 8.15
(d, J = 5.6 Hz, 1H), 8.47 (d, J = 5.2 Hz, 1H), 9.20 (br s, 1H, NH),
9.29 (br s, 1H, NH) ppm. 13C NMR (DMSO-d6, 100.6 MHz): d
103.6 (C), 115.1 (CH), 118.2 (2  CH), 118.4 (C), 119.2 (C), 119.6
(2  CH), 125.0 (CH), 129.5 (C), 131.8 (CH), 133.3 (2  CH), 136.1
(2  CH), 141.2 (C), 143.6 (C), 143.9 (C), 147.5 (CH), 151.9 (C),
155.7 (C) ppm. MS (ESI- TOF) m/z (%): 403.07 (M++H, 100) HRMS
(ESI-TOF): calcd for C21H15N4OS2 [M++H] 403.0682, found
403.0681. Anal. Calcd for C21H14N4OS2: C, 62.67; H, 3.51; N,
13.92; S, 15.93%. Found: C 62.85; H, 3.73; N, 13.57; S, 15.55%.
4.1.2.15. 1-[3-(Trifluoromethyl)phenyl]-3-[4-(thieno[3,2b]pyri-
din-7-ylthio)phenyl]urea (5d). From 4-(thieno[3,2-b]pyridine-
7-ylthio)aniline (90.8 mg, 0.351 mmol) and 3-(trifluoromethyl)
phenyl-isocyanate (65.8 mg, 0.351 mmol, 48.4 lL) compound 5d
was isolated as a colourless solid (86.0 mg, 55%). Mp 162–164 C.
1H NMR (DMSO-d6, 400 MHz): 6.74 (d, J = 4.8 Hz, 6000-H), 7.33 (br
d, 40-H), 7.52 (apparent t, J = 8.0 Hz, 50-H), 7.56–7.61 (m, 4H),
7,65 (d, J = 9.0 Hz, 2H), 8.01 (br s, 20-H), 8.15 (d, J = 5.6 Hz, 1H),
8.47 (d, J = 4.8 Hz, 5000-H), 9.13 (s, NH), 9.14 (s, NH). 13C NMR
(DMSO-d6, 100.6 MHz): 114.3 (q, J = 4.0 Hz, 20-CH), 115.1 (6000-CH),
118.4 (q, J = 4.0 Hz, 50-CH), 119.36 (C), 119.63 (2  CH), 122.0
(CH), 122.83 (C), 124.2 (q, J = 271.6 Hz, CF3), 125.0 (CH), 129.5 (q,
J = 31.2 Hz, CCF3), 129.6 (C), 130.0 (40-CH), 131.8 (CH), 136.1
(2  CH), 140.3 (C), 141.5 (C), 143.7 (C), 147.5 (5000-CH), 152.3 (C),
155.7 (C) ppm. MS (ESI) m/z (%): 446.25 (M++H, 100). Anal. Calcd
for C21H14F3N3OS2: C, 56.62; H, 3.17; N, 9.43; S, 14.40%. Found: C
56.30; H, 3.26; N, 9.73; S, 14.78%.
4.1.2.16. 1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-[4-(thieno-
[3,2-b]pyridin-7-ylthio)phenyl]urea (5e). From 4-(thieno[3,2-
b]pyridine-7-ylthio)aniline (101.8 mg, 0.394 mmol) and 4-chloro-
3-(trifluoromethyl)phenyl-isocyanate (87.3 mg, 0.394 mmol)
compound 5e was isolated as a light yellow solid (136 mg, 72%).
Mp 224–226 C. 1H NMR (DMSO-d6, 400 MHz): 6.74 (d, J = 4.8 Hz,
6000-H), 7.56–7.66 (m, 7H), 8.1 (d, J = 2.4 Hz, 20-H), 8.15
(d, J = 5.2 Hz, 1H), 8.47 (d, J = 4.8 Hz, 5000-H), 9.18 (s, NH), 9.25
(s, NH). 13C NMR (DMSO-d6, 100.6 MHz): 115.1 (6000-CH),
117.0 (q, J = 6.0 Hz, 20-CH), 119.7 (2  CH), 122.5 (C) 122.6 (C)
122.8 (q, J = 272.6 Hz, CF3), 123.3 (CH), 125.0 (CH), 126.7
(q, J = 30.2 Hz, CCF3), 129.5 (C), 131.8 (CH), 132.0 (CH), 136.1
(2  CH) 139.1 (C), 141.3 (C), 143.6 (C), 147.4 (5000-CH), 152.2 (C),
155.7 (C) ppm. MS (ESI) m/z (%): 480.17 (M+ 35Cl+H, 100), 482.17
(M+ 37Cl+H, 29). Anal. Calcd for C21H13ClF3N3OS2: C, 52.55; H,
2.73; N, 8.76; S, 13.36%. Found: C 52.25; H, 2.75; N, 8.66; S, 13.46%.
4.2. VEGFR-2 kinase inhibition assay
The compounds were assessed for VEGFR-2 inhibitory activity
using the Z0-LYTE-Tyr1 Peptide assay kit (Invitrogen, Cat.
PV3190) and according to the procedures recommended by themanufacturer.12 Briefly, assays were performed in a total of 20 lL
in 384-well plates using fluorescence resonance energy transfer
technology. A Tyr1 substrate (coumarin-fluorescein double-labeled
peptide) at 1 lM was incubated for 1 h with 4 lg/mL VEGFR-2,
10 lM ATP, and inhibitors at room temperature in 50 mM Hepes/
NaOH (pH 7.5), 10 mM MgCl2, 2 mM MnCl2, 2.5 mM DTT,
0.10 mM orthovanadate, and 0.01% bovine serum albumin (BSA).
Inhibitors were added to the wells with 4% DMSO added as solvent.
The wells were incubated at 25 C for 1 h and 5 lL of development
reagent was added to each well. After a second incubation of 1 h
the stop reagent was added to each well. Using a Biotek FLX800
micro-plate the fluorescence was read at 445 nm and 520 nm
(excitation 400 nm), and Gen5TM Software was used for data analy-
sis. The validation assay was performed using Staurosporine that
present an IC50 value 6 nM that compares to the one reported in
the literature.16
4.3. Molecular docking protocol
VEGFR-2 crystal structure (PDB: 3VHE) was extracted from the
Protein Data Bank (PDB) (http://www.rcsb.org). The co-crystallized
ligand was extracted from the PDB file, and AutoDockTools was
used to assign polar hydrogens and Gasteiger charges. AutoGrid4
was used to create affinity grid maps for all atom types. The affinity
grids enclosed a volumetric space of 100 Å by 100 Å by 100 Å, with
0.375 Å spacing, centered on the coordinates x = 86.3, y = 51.2,
z = 48.3. AutoDock4 (version 4.1) with the Lamarckian genetic
algorithm was used with the following docking parameters: 100
docking runs, population size of 200, random starting position
and conformation, translation step ranges of 2.0 Å, mutation rate
of 0.02, crossover rate of 0.8, local search rate of 0.06, 2.5 and 25
million energy evaluations.23 Docked conformations were clus-
tered using a tolerance of 2.0 Å RMSD. The entire virtual experi-
ment was performed on a cluster of 64 AMD 2.0 GHz processor,
using software MOLA.24 The 3D compound-protein docking poses
were analyzed manually using AutoDockTools, and Figure 1 was
prepared using the software PyMOL.18
4.4. Biological assays
4.4.1. HUVECs culture
HUVECs were obtained from the Science Cell Research Labs (San
Diego, CA, USA). HUVECs were harvested in gelatin-coated culture
plates in M199 medium (Sigma–Aldrich, Sintra, Portugal) supple-
mented with 20% fetal bovine serum (FBS), 1% penicillin/strepto-
mycin (Invitrogen Life Technologies, Scotland, UK), 0.01% heparin
(Sigma–Aldrich), and 30 mg/mL endothelial cell growth supple-
ment (Biomedical Technologies Inc., MA, USA) and maintained at
37 C in a humidified atmosphere containing 5% CO2. The tested
compounds were dissolved in DMSO and added to cell cultures
at a concentration of 0.1–10 lM. Treatments were performed dur-
ing 24 h in medium supplemented with 2% FBS, 1% penicillin/
streptomycin, and 60 ng/mL of the vascular endothelial growth
factor (VEGF) (Sigma-Aldrich, Portugal). Control cells were treated
with vehicle (0.1% DMSO).
4.4.2. HUVECs viability assay
HUVECs were seeded (2  105 cells/mL) in 96-well plate,
allowed to grow for 24 h and then incubated with different dilu-
tions of tested compounds at a range concentration between 0.1
and 10 lM or control (0.1% DMSO), in the presence of VEGF, for
24 h. After the incubation period, cells were washed with PBS
and their viability was assessed using Cell Titer 96 Aqueous ONE
Solution Reagent MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-car-
boxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] colori-
metric assay (Promega, Madison, USA), according to the
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described.25 Optical density was measured at 492 nm.
4.4.3. HUVECs proliferation assay
HUVECs (6  104 cells/mL) were grown during 24 h and then
incubated with compounds at 0.1–10 lM or control (0.1% DMSO),
in the presence of VEGF, for 24 h. Cells were also incubated with
50-bromodeoxyuridine (BrdU) solution at a final concentration of
0.01 mM during the treatment period. Optical density of proliferat-
ing cells (positive for BrdU) after ELISA assay using anti-BrdU-
specific antibodies (Roche Diagnostics, Mannheim, Germany) was
evaluated at the microplate reader according to the manufacturer’s
instructions and as previously reported.26 Results were expressed
as percentage of control (100%).
4.4.4. HUVECs migration assay: wound-healing
HUVECs were seeded in a 24-well plates pre-coated with 0.1%
gelatin and were allowed to grow to 100% confluence. Cell culture
were injured by a 10 lL tip, cells were washed twice with PBS, and
then incubated with fresh medium containing VEGF with or with-
out the compounds in study at different concentrations for 24 h.
Cell migration to the damaged area was then visualized and pho-
tographed on a phase contrast microscope (Nikon) at a magnifica-
tion of 100.25 Inhibition percentage was expressed as percentage
of the control (100%).
4.4.5. HUVECs capillary-like tube formation assay
Matrigel basement membrane matrix (growth factor reduced)
(Corning, USA) was thawed at 4 C, pipetted into pre-chilled 24-
well plates (200 lL matrigel/well) and incubated at 37 C for
30 min. Then HUVECs (8  104 cells/mL) were added to matrigel
coated plates, followed by addition of various concentrations of
compounds in study with VEGF (60 ng/mL). After 24 h of incuba-
tion with 5% CO2 at 37 C, the number of capillary-like tube forma-
tion of each well was photographed using a phase-contrast
microscope (Nikon, UK) at 100 magnifications. Tube formation
was quantitated by manual counting the number of branch
points.25 All experiments were done in triplicate. Inhibition per-
centage was expressed as percentage of control (100%).
4.4.6. Western blotting analysis
In brief, proteins were isolated from HUVEC lysates using RIPA
(Chemicon International, CA, USA) and 20 lg of protein were sep-
arated by 8% SDS-PAGE and transferred to Hybond nitrocellulose
membrane (Amersham, Arlington, VA, USA). Membranes were then
incubated with primary antibodies including phosphorylated (acti-
vated) VEGFR-2 (Santa Cruz Biotechnology, CA, USA), total VEGFR-
2 (Cell Signalling, MA, USA) and b-actin (Abcam, Cambridge, UK).
After overnight incubation at 4 C, membranes were washed with
TBST and incubated with secondary antibodies at room tempera-
ture for 1 h. Immunoreactive bands were then visualized by the
enhanced chemiluminescence detection system (ECL kit, Amer-
sham, Arlington, USA).26
4.4.7. Statistical analyses
All experiments were performed at least in three independent
experiments. Data are expressed as mean ± SEM. The significance
of the differences between the means observed was evaluated
using the one-way ANOVA followed by Bonferroni test. p <0.05
was considered statistically significant.Acknowledgments
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